A fecal lactoferrin test measures an iron-binding protein released mainly by activated neutrophils in the digestive tract. When these white blood cells enter the intestinal lining and lumen, stool lactoferrin rises. The test can help distinguish inflammatory diarrhea from functional conditions such as irritable bowel syndrome and can support monitoring in inflammatory bowel disease (IBD). However, a high result does not identify the cause. Ulcerative colitis, Crohn disease, bacterial colitis, Clostridioides difficile infection, and other disorders can all increase it. A normal result makes substantial neutrophil-driven intestinal inflammation less likely but does not exclude every form or location of IBD. Results also depend on the assay and sample handling, so the laboratory’s own cutoff should be used. This article explains what lactoferrin measures, how it compares with fecal calprotectin, what high levels can mean, and when stool testing should lead to infection studies, endoscopy, imaging, or urgent medical care.
- What it measures: Lactoferrin released into stool during neutrophil-rich intestinal inflammation.
- Main clinical use: Supporting the distinction between inflammatory bowel disease or infectious colitis and noninflammatory causes of symptoms.
- What high means: Active gastrointestinal inflammation is possible, but the result does not separate IBD from infection or other causes.
- What normal means: Significant colonic inflammation is less likely, though mild, patchy, or isolated small-bowel disease may still be present.
- Important comparison: Fecal lactoferrin and calprotectin are related stool markers, but their assays and thresholds are not interchangeable.
Table of Contents
- What fecal lactoferrin measures
- Normal, borderline, and high results
- Causes of high fecal lactoferrin
- How the test is used in IBD
- Infection and other conditions that affect the test
- Lactoferrin compared with calprotectin
- Next steps, treatment, and urgent warning signs
What Fecal Lactoferrin Measures
Lactoferrin is a protein found in neutrophil granules and in secretions such as breast milk, tears, and saliva. It binds iron and participates in antimicrobial defense and immune regulation. In the stool test, the clinically important source is neutrophils that migrate into inflamed intestinal tissue and release their contents.
Neutrophils are prominent in active ulcerative colitis, many Crohn disease lesions, and bacterial colitis. Their presence in the intestinal lumen makes fecal lactoferrin a marker of mucosal inflammation rather than a general blood marker. Unlike a white-blood-cell microscopy test, an immunoassay detects the stable protein and can be reported qualitatively as positive or negative or quantitatively in micrograms per gram of stool.
The test may be ordered for persistent or recurrent diarrhea, abdominal pain, blood or mucus in stool, weight loss, fever, or suspected IBD. In a person with known IBD, it may help assess whether symptoms are likely to reflect active inflammation and whether treatment is reducing neutrophil activity. It cannot show the exact location, depth, or cause of inflammation.
A small stool sample is collected in a clean container. Urine, toilet water, cleaning chemicals, and excessive dilution should be avoided. Laboratories provide specific instructions for storage and transport. Some assays permit short periods at room temperature or refrigeration; others prefer frozen samples. Delayed or improper handling can reduce reliability.
Medicines and recent events should be discussed. Antibiotics may change an infectious illness, while anti-inflammatory therapy may reduce the marker. Gastrointestinal bleeding, recent endoscopy, severe constipation, and age-related conditions can affect the broader interpretation even if they do not create a predictable change in every assay.
The test does not measure lactoferrin from food or supplements in a way that can be interpreted as intestinal inflammation. Human and bovine lactoferrin products have different biological contexts from neutrophil-derived fecal lactoferrin. Stopping a supplement is not usually required unless the laboratory or clinician gives that instruction.
Normal, Borderline, and High Results
Cutoffs depend on the commercial method. Some tests provide only a positive or negative result. Quantitative assays report a concentration, and the normal upper limit may differ substantially between laboratories. One current assay uses 4.4 µg/g as its upper reference value, but that number should not be transferred to a different platform.
| Result | General meaning | Typical clinical response |
|---|---|---|
| Normal or negative | No strong evidence of active neutrophil-rich intestinal inflammation | Consider functional disease or other noninflammatory causes if there are no alarm features |
| Borderline or near cutoff | Could reflect mild inflammation, recovery, variation, or assay uncertainty | Review symptoms, infection risk, medicines, and whether repeat testing is appropriate |
| High or positive | Active gastrointestinal inflammation is likely | Investigate IBD, infection, and other organic disease according to the clinical setting |
| Persistently high in known IBD | Ongoing mucosal inflammatory activity is possible | Assess adherence, infection, treatment response, and need for endoscopy or imaging |
| Falling trend | Neutrophil activity may be improving | Interpret with symptoms and objective disease targets |
The result is not a severity score that can be compared directly between every patient. A high value does not reveal whether inflammation is limited to the rectum, spread through the colon, or located in the small intestine. It also cannot determine whether tissue damage is superficial or deep.
A negative test has the greatest value when the pretest probability of IBD is low to moderate and there are no alarm features. In that setting, it can support a less invasive approach. If a person has rectal bleeding, iron-deficiency anemia, nocturnal diarrhea, fever, substantial weight loss, a family history of colorectal cancer, or an abnormal examination, further investigation may be needed despite a normal value.
Biological variability matters. Neutrophil shedding can change from one bowel movement to another, especially with patchy disease. Serial samples are best compared using the same assay and laboratory. A change after switching methods may be analytical rather than biological.
Stool consistency may influence concentration. Very watery samples can dilute some analytes, while prolonged retention could alter distribution. The laboratory’s validation and rejection rules should be followed. A clinician may repeat an unexpected result rather than base an invasive decision on a single discordant sample.
Causes of High Fecal Lactoferrin
A high result indicates neutrophils are entering the gastrointestinal tract, but several diseases can produce that response.
Inflammatory Bowel Disease
Ulcerative colitis causes continuous mucosal inflammation beginning in the rectum, often with blood, urgency, and diarrhea. Crohn disease can affect any part of the digestive tract and may be patchy or involve deeper layers. Active colonic disease in either condition commonly raises fecal lactoferrin. Isolated small-bowel Crohn disease may generate a weaker stool signal in some patients.
Infectious Colitis
Bacterial pathogens can trigger intense neutrophil recruitment. Campylobacter, Salmonella, Shigella, invasive Escherichia coli, and C. difficile are examples. The lactoferrin result does not identify the organism, determine whether antibiotics are appropriate, or distinguish infection from an IBD flare. Stool molecular tests, culture, toxin testing, travel history, food exposure, and antibiotic history provide that information.
Other Inflammatory or Structural Disorders
Ischemic colitis, diverticulitis involving the bowel lumen, colorectal cancer, some polyps, radiation injury, and medication-related colitis can increase fecal inflammatory markers. In infants, necrotizing enterocolitis is an important inflammatory condition, but pediatric interpretation requires age-specific expertise. Untreated celiac disease usually causes a different immune pattern but may occasionally be associated with elevated stool markers when mucosal injury is substantial.
Recent Treatment or Resolving Illness
The marker may stay high while tissue is healing or fall before every symptom resolves. After infectious diarrhea, bowel habits can remain abnormal because of postinfectious irritable bowel syndrome even when neutrophilic inflammation has cleared. In IBD, symptoms can persist from strictures, bile-acid diarrhea, pelvic-floor dysfunction, or visceral hypersensitivity despite a low lactoferrin.
A high value should not be assumed to come from food intolerance, stress, or irritable bowel syndrome. Those conditions can cause genuine symptoms, but they do not typically produce neutrophil-rich mucosal inflammation. If lactoferrin is clearly elevated, an organic cause should be sought.
How the Test Is Used in IBD
Fecal lactoferrin can contribute at several points in IBD care: initial triage, assessment of a symptomatic flare, monitoring of treatment, and evaluation for relapse. It is an adjunct rather than a replacement for endoscopy, histology, and imaging.
At initial presentation, a normal stool inflammatory marker makes IBD less likely than a functional disorder in an otherwise low-risk patient. A high marker supports referral or further testing but cannot distinguish Crohn disease from ulcerative colitis. Diagnosis relies on the pattern of symptoms, colonoscopy with biopsies, and imaging of the small bowel when indicated.
In established IBD, symptoms alone can mislead. Some people have silent inflammation, while others have diarrhea and pain from noninflammatory causes. Lactoferrin can help separate these possibilities. A high value during worsening symptoms raises concern for active disease or infection. A low value prompts consideration of irritable-bowel overlap, medication side effects, bile-acid malabsorption, small-intestinal bacterial overgrowth, or structural complications.
Monitoring is most useful when a person’s baseline relationship between the marker and endoscopic activity is known. A falling result after therapy supports reduced neutrophil activity. Persistent elevation despite symptom improvement may lead to treatment review or objective assessment. Conversely, a low value does not always prove mucosal healing, especially in isolated ileal disease or mild patchy activity.
Treat-to-target IBD care aims beyond symptom relief toward objective control of inflammation. Fecal markers reduce the need for repeated invasive procedures but do not eliminate them. Endoscopy remains important for diagnosis, dysplasia surveillance, assessment of healing, and evaluation when stool markers and symptoms disagree.
Infection should be excluded before escalating immune-suppressing treatment. C. difficile is particularly important because it can mimic or worsen an IBD flare. Other stool pathogen testing depends on severity, travel, exposures, immune status, and local epidemiology.
Infection and Other Conditions That Affect the Test
Acute diarrhea is often infectious and self-limited. A positive fecal lactoferrin indicates an inflammatory response but does not automatically mean antibiotics are needed. Some bacterial infections improve without antibiotics, while certain toxin-producing E. coli infections may be harmed by inappropriate antibiotics. Clinical severity and organism-specific testing guide treatment.
Features that increase the likelihood of inflammatory infection include fever, blood or mucus, severe abdominal cramps, dehydration, recent travel, contaminated food or water, outbreak exposure, and immune suppression. Recent antibiotics or health-care contact raises concern for C. difficile. Stool testing is selected according to these risks.
Lactoferrin cannot diagnose parasitic infection. Some parasites cause inflammatory diarrhea, while others produce watery symptoms without a strong neutrophil response. Ova-and-parasite or antigen and molecular tests are used when exposure and duration justify them.
Medication history matters. Nonsteroidal anti-inflammatory drugs can injure the intestinal lining and may increase fecal inflammatory markers. Immune-checkpoint inhibitors, antibiotics, and other medicines can cause colitis. Proton-pump inhibitors are more clearly linked to changes in fecal calprotectin in some studies than to a consistent lactoferrin effect, but they can alter infection risk and symptom interpretation.
Colorectal neoplasia can cause bleeding and inflammation, yet lactoferrin is not a cancer-screening test. A negative result does not replace age-appropriate screening or diagnostic colonoscopy for rectal bleeding, anemia, or weight loss. Similarly, it cannot detect every cause of malabsorption or pancreatic insufficiency.
Blood inflammatory markers such as CRP may complement stool testing. CRP reflects systemic hepatic response and may be normal in localized bowel inflammation. Fecal lactoferrin is closer to the intestinal mucosa but can be high from infection. Using both can clarify whether inflammation appears local, systemic, or discordant.
Lactoferrin Compared With Calprotectin
Fecal lactoferrin and fecal calprotectin are both released in association with neutrophils and are resistant enough to degradation to be measured in stool. They serve similar clinical purposes: helping distinguish inflammatory from functional gastrointestinal disease and monitoring IBD activity.
The fecal calprotectin test has a larger evidence base, broader guideline integration, and more widely used quantitative thresholds. Lactoferrin remains a useful alternative or complementary marker, particularly where a validated assay is established. Neither has perfect sensitivity or specificity.
Key differences include:
- Protein biology: Calprotectin is a calcium- and zinc-binding complex abundant in neutrophil cytosol; lactoferrin is an iron-binding glycoprotein in neutrophil granules and secretions.
- Reporting: Lactoferrin may be qualitative or quantitative; calprotectin is commonly quantitative.
- Cutoffs: Each assay has its own threshold, and numerical values cannot be converted between the markers.
- Evidence: More studies and treatment algorithms currently use calprotectin, especially for relapse prediction and treat-to-target monitoring.
- Limitations: Both rise with infectious colitis and other organic inflammation and may be less sensitive for isolated small-bowel disease.
Ordering both at the same time is not always necessary because they often provide overlapping information. A clinician may choose one based on local validation, availability, cost, previous results, and the specific care pathway. Switching between markers during follow-up can make trends harder to interpret.
Direct stool leukocyte microscopy is less standardized and more dependent on fresh sample handling and observer skill. Lactoferrin offers a more stable biochemical indicator of neutrophils but still cannot replace microbiology or tissue diagnosis.
Next Steps, Treatment, and Urgent Warning Signs
The appropriate next step depends on the result and the clinical risk. A normal value in a person with mild chronic abdominal discomfort, stable weight, and no bleeding may support evaluation for irritable bowel syndrome, dietary triggers, celiac disease, or other noninflammatory causes. Persistent symptoms still deserve care even when inflammation is unlikely.
A high value may lead to stool pathogen testing, blood count, CRP, electrolytes, liver tests, and assessment of hydration. If infection is excluded and IBD is suspected, gastroenterology evaluation, colonoscopy with biopsies, and small-bowel imaging may follow. In known IBD, clinicians review medication adherence, recent infections, drug levels or antibodies when relevant, and the need for endoscopic reassessment.
Treatment targets the cause. IBD may require aminosalicylates, corticosteroids, immunomodulators, biologic medicines, small molecules, nutrition therapy, or surgery according to disease type and severity. Bacterial or parasitic infection is treated selectively. Functional bowel disorders are managed with a different strategy; anti-inflammatory therapy is not appropriate simply because symptoms resemble IBD.
There is no evidence-based home treatment aimed solely at lowering fecal lactoferrin. The marker should decline as neutrophil-rich inflammation improves. Repeating it too frequently can create noise because biological and analytical variation may exceed small changes. The interval should match the clinical question and expected treatment response.
Seek urgent care for severe dehydration, inability to keep fluids down, fainting, confusion, a rigid or markedly swollen abdomen, severe persistent pain, black stool, large-volume rectal bleeding, rapid heartbeat with weakness, or high fever with deterioration. Children, older adults, pregnant people, and immunocompromised patients can become seriously ill more quickly.
Prompt medical review is appropriate for nocturnal diarrhea, persistent blood, anemia, weight loss, fever, recurrent vomiting, growth problems in a child, or symptoms lasting more than several weeks. A stool marker is a guide to the next diagnostic step—not a substitute for evaluating alarm features.
When a result conflicts with the clinical picture, repeating the stool sample can be reasonable before changing long-term treatment, provided there are no urgent warning signs. Clinicians also check whether the sample was collected during menstruation or visible rectal bleeding, whether an infection was already improving, and whether immunosuppressive treatment began before collection. A single number should not outweigh a clear deterioration in symptoms, and a mildly abnormal number should not automatically trigger treatment escalation without confirming the cause.
References
- LCTF – Overview: Lactoferrin, Feces 2025
- Inflammatory Bowel Disease 2025
- Calprotectin, Fecal by Immunoassay 2025
- Diagnostic Value of Fecal Lactoferrin in Differentiating Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Comparative Study 2025
- Trajectory of Fecal Lactoferrin for Predicting Prognosis in Ulcerative Colitis 2023
- The Utility of Faecal Calprotectin, Lactoferrin and Other Faecal Biomarkers in Discriminating Endoscopic Activity in Crohn’s Disease: A Systematic Review and Meta-Analysis 2023
Disclaimer
This article is for general education and cannot diagnose IBD, infection, cancer, or another cause of gastrointestinal symptoms. Fecal lactoferrin assays and cutoffs differ, and results must be interpreted with symptoms, microbiology, endoscopy, imaging, and medical history. Seek urgent care for severe bleeding, dehydration, intense abdominal pain, or rapid deterioration.
